GlassScriptPhysician profile
Ryan D Landefeld
NPI 1245262062
$8,288.83
in general payments reported to CMS, 2019-2025
44 companies · $1,967 in 2025
The $1,967 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $463 · 2021: $24.46 · 2022: $1,334 · 2023: $1,924 · 2024: $1,587 · 2025: $1,967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,477.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,056.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $698.37 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $616.30 | 2019-2025 | Repatha, Evenity, Prolia |
| Abbvie INC. | $446.17 | 2019-2025 | |
| Pfizer INC. | $439.56 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $404.96 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $373.55 | 2019-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $370.47 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $361.29 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $347.24 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $284.37 | 2019-2023 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.58 | 2019-2025 | Ofev, Jardiance, Synjardy |
| E.R. Squibb & Sons, L.L.C. | $228.08 | 2019-2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $207.44 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $170.15 | 2022-2025 | Dexcom G6 Transmitter |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $169.04 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $161.54 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $119.37 | 2022-2024 | Quviviq |
| Lundbeck LLC | $108.61 | 2024-2025 | Rexulti |
| Boston Scientific Corporation | $108.48 | 2024-2025 | Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $107.15 | 2019-2024 | Trintellix |
| Madrigal Pharmaceuticals | $103.75 | 2024-2025 | Rezdiffra, Resmetirom |
| Inspire Medical Systems, INC. | $103.74 | 2024-2025 | Inspire |
| Viatris Specialty LLC | $89.61 | 2025 | Yupelri |
| Shield Therapeutics INC | $83.16 | 2023-2025 | Accrufer |
| Phathom Pharmaceuticals, INC. | $76.91 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.74 | 2020-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $75.55 | 2025 | Rexulti |
| Amarin Pharma, INC. | $70.05 | 2019-2022 | |
| Eisai INC. | $63.60 | 2024-2025 | |
| Daiichi Sankyo INC. | $63.10 | 2019-2023 | Injectafer |
| Ferring Pharmaceuticals INC. | $53.70 | 2023-2024 | Rebyota |
| Mylan Specialty L.P. | $52.83 | 2024 | Yupelri |
| Corcept Therapeutics | $50.64 | 2020-2025 | Korlym |
| Abbott Laboratories | $48.54 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi Pasteur INC. | $37.61 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $33.86 | 2020-2025 | Zoryve |
| Amneal Pharmaceuticals LLC | $33.03 | 2019-2023 | Unithroid |
| Alexion Pharmaceuticals, INC. | $31.51 | 2024 | Ultomiris |
| Radius Health, INC. | $28.02 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.05 | 2025 | Caplyta |
| Esperion Therapeutics, INC. | $20.04 | 2025 | Nexletol |
| Acadia Pharmaceuticals INC | $16.19 | 2025 | Nuplazid |
| Medtronic, INC. | $14.74 | 2025 | Interstim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Landefeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.